Our Firm is representing a number of clients in GranuFlo lawsuits, and we continue hear from individuals who allegedly suffered potentially deadly heart events following the administration of GranuFlo and NaturaLyte.
New York, New York (PRWEB) February 21, 2014
GranuFlo lawsuits (http://www.thegranuflolawsuit.com/ ) filed in the aftermath of the 2012 recall of GranuFlo and NaturaLyte dialysis drugs continue to mount in federal court, Bernstein Liebhard LLP reports. According to an updated docket report issued by the U.S. Judicial Panel for Multidistrict Litigation (JPML) on February 19, 2014, 515 GranuFlo recall claims are now pending in the U.S. District Court, District of Massachusetts, where federally-filed cases have been consolidated for pretrial proceedings. When the federal multidistrict litigation was first established in March 2013, only 11 cases were initially transferred to the District of Massachusetts by the JPML. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“Our Firm is representing a number of clients in GranuFlo lawsuits, and we continue hear from individuals who allegedly suffered potentially deadly heart events following the administration of GranuFlo and NaturaLyte. It is not surprising that the number of GranuFlo recall claims filed in this proceeding has surpassed 500 in less than a year,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other serious heart events within 72 hours of the administration of GranuFlo or NaturaLyte.
According to court documents, all of the GranuFlo lawsuits pending in the District of Massachusetts were filed on behalf of dialysis patients who allegedly suffered serious and/or fatal heart events following the administration of GranuFlo or NaturaLyte acid concentrates during dialysis treatments. The lawsuits further allege that the products caused recipients to suffer metabolic alkalosis, a dangerous elevation of bicarbonate in the blood that may result in cardiac arrest, cardiac arrhythmia, and other sudden and catastrophic heart problems. Among other things, plaintiffs accuse Fresenius Medical Care of concealing its knowledge of the risks associated with GranuFlo and NaturaLyte, and failing to provide adequate instructions and warnings regarding their use.
In addition to the GranuFlo recall lawsuits pending in federal court, a number of similar cases have been consolidated at the state level in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)
Both GranuFlo and NaturaLyte were subject to a Class I recall in June 2012, following the release of an Urgent Product Notification by Fresenius in March of that year that warned dialysis clinics nationwide of possible dosage issues that could result in metabolic alkalosis. A Class I recall is the U.S. Food & Drug Administration’s (FDA) most serious safety notice, and signifies that a medical product poses a risk of serious injury or death.
According to a New York Times report published in June 2012, the FDA is investigating Fresenius Medical Care’s handling of the GranuFlo recall, after becoming aware of a memo the company issued in November 2011 to its own clinics regarding the risks associated with GranuFlo and NaturaLyte. However, nothing was done at that time to notify thousands of dialysis centers outside the Fresenius network about the potential dangers associated with the products.*
Victims of serious heart problems that were allegedly caused by GranuFlo or NaturaLyte may be eligible to file their own GranuFlo lawsuit. To learn more about the GranuFlo recall, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For more information, and to arrange for a free case review, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP